Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
896
archived clinical trials in
Gastroesophageal Reflux Disease

Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors
A Phase 2a Study to Evaluate the Effect of IW-3718 Administered Orally for 4 Weeks in Patients With GERD Not Completely Responsive to Proton Pump Inhibitors
Status: Enrolling
Updated:  8/10/2015
Ironwood Investigational Site
mi
from
South Ogden, UT
Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors
A Phase 2a Study to Evaluate the Effect of IW-3718 Administered Orally for 4 Weeks in Patients With GERD Not Completely Responsive to Proton Pump Inhibitors
Status: Enrolling
Updated: 8/10/2015
Ironwood Investigational Site
mi
from
South Ogden, UT
Click here to add this to my saved trials
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients
Status: Enrolling
Updated:  8/19/2015
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients
Status: Enrolling
Updated: 8/19/2015
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Click here to add this to my saved trials
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients
Status: Enrolling
Updated:  8/19/2015
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients
Status: Enrolling
Updated: 8/19/2015
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Click here to add this to my saved trials
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients
Status: Enrolling
Updated:  8/19/2015
Catalina Research Institute
mi
from
Chino, CA
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients
Status: Enrolling
Updated: 8/19/2015
Catalina Research Institute
mi
from
Chino, CA
Click here to add this to my saved trials
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients
Status: Enrolling
Updated:  8/19/2015
Jupiter Research
mi
from
Jupiter, FL
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients
Status: Enrolling
Updated: 8/19/2015
Jupiter Research
mi
from
Jupiter, FL
Click here to add this to my saved trials
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients
Status: Enrolling
Updated:  8/19/2015
Columbus Regional Research Institute
mi
from
Columbus, GA
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients
Status: Enrolling
Updated: 8/19/2015
Columbus Regional Research Institute
mi
from
Columbus, GA
Click here to add this to my saved trials
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients
Status: Enrolling
Updated:  8/19/2015
MedPharmics, LLC.
mi
from
Metairie, LA
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients
Status: Enrolling
Updated: 8/19/2015
MedPharmics, LLC.
mi
from
Metairie, LA
Click here to add this to my saved trials
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients
Status: Enrolling
Updated:  8/19/2015
Investigative Clinical Research
mi
from
Annapolis, MD
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients
Status: Enrolling
Updated: 8/19/2015
Investigative Clinical Research
mi
from
Annapolis, MD
Click here to add this to my saved trials
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients
Status: Enrolling
Updated:  8/19/2015
MGG Group, Co. Inc./Chevy Chase Clinical Research
mi
from
Chevy Chase, MD
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients
Status: Enrolling
Updated: 8/19/2015
MGG Group, Co. Inc./Chevy Chase Clinical Research
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients
Status: Enrolling
Updated:  8/19/2015
Detroit Clinical Research Center PC
mi
from
Farmington Hills, MI
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients
Status: Enrolling
Updated: 8/19/2015
Detroit Clinical Research Center PC
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients
Status: Enrolling
Updated:  8/19/2015
Office of Stephen Miller, M.D.
mi
from
Las Vegas, NV
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients
Status: Enrolling
Updated: 8/19/2015
Office of Stephen Miller, M.D.
mi
from
Las Vegas, NV
Click here to add this to my saved trials
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients
Status: Enrolling
Updated:  8/19/2015
Peters Medical Research
mi
from
HIgh Point, NC
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients
Status: Enrolling
Updated: 8/19/2015
Peters Medical Research
mi
from
HIgh Point, NC
Click here to add this to my saved trials
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients
Status: Enrolling
Updated:  8/19/2015
Wake Research Associates, LLC
mi
from
Raleigh, NC
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients
Status: Enrolling
Updated: 8/19/2015
Wake Research Associates, LLC
mi
from
Raleigh, NC
Click here to add this to my saved trials
Efficacy of Combination Therapy vs Placebo for Pediatric Functional Abdominal Pain
Efficacy of Combination Therapy vs Placebo for Pediatric Functional Abdominal Pain
Status: Enrolling
Updated:  8/21/2015
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Efficacy of Combination Therapy vs Placebo for Pediatric Functional Abdominal Pain
Efficacy of Combination Therapy vs Placebo for Pediatric Functional Abdominal Pain
Status: Enrolling
Updated: 8/21/2015
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
The EndoGastric Solutions TEMPO Trial
Transoral Incisionless Fundoplication (TIF) Versus Medical Proton Pump Inhibitor (PPI) Management of Refractory Gastroesophageal Reflux Disease (GERD) Symptoms
Status: Enrolling
Updated:  8/31/2015
EndoGastric Solutions
mi
from
Redwood City, CA
The EndoGastric Solutions TEMPO Trial
Transoral Incisionless Fundoplication (TIF) Versus Medical Proton Pump Inhibitor (PPI) Management of Refractory Gastroesophageal Reflux Disease (GERD) Symptoms
Status: Enrolling
Updated: 8/31/2015
EndoGastric Solutions
mi
from
Redwood City, CA
Click here to add this to my saved trials
Is the Neosquamous Epithelium "Normal" Following Endoscopic Ablation of Dysplastic Barrett's Esophagus?
Is the Neosquamous Epithelium "Normal" Following Endoscopic Ablation of Dysplastic Barrett's Esophagus?
Status: Enrolling
Updated:  9/21/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Is the Neosquamous Epithelium "Normal" Following Endoscopic Ablation of Dysplastic Barrett's Esophagus?
Is the Neosquamous Epithelium "Normal" Following Endoscopic Ablation of Dysplastic Barrett's Esophagus?
Status: Enrolling
Updated: 9/21/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Racial Disparity in Barrett's Esophagus
Racial Disparity in Barrett's Esophagus
Status: Enrolling
Updated:  9/21/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Racial Disparity in Barrett's Esophagus
Racial Disparity in Barrett's Esophagus
Status: Enrolling
Updated: 9/21/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
To Learn How Bone Structure and Bone Mass Change After Long-term PPI Use
Effect of Chronic Proton Pump Inhibitor Therapy on Bone Mineral Density and Bone Structure in Mid to Late Adulthood
Status: Enrolling
Updated:  10/7/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
To Learn How Bone Structure and Bone Mass Change After Long-term PPI Use
Effect of Chronic Proton Pump Inhibitor Therapy on Bone Mineral Density and Bone Structure in Mid to Late Adulthood
Status: Enrolling
Updated: 10/7/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Quantifying Effects of Treatment of Pediatric Dysphonia
Quantifying Effects of Treatment of Pediatric Dysphonia
Status: Enrolling
Updated:  10/13/2015
University of Wisconsin
mi
from
Madison, WI
Quantifying Effects of Treatment of Pediatric Dysphonia
Quantifying Effects of Treatment of Pediatric Dysphonia
Status: Enrolling
Updated: 10/13/2015
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated:  10/15/2015
Clinical Research Facility
mi
from
Moline, IL
Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 10/15/2015
Clinical Research Facility
mi
from
Moline, IL
Click here to add this to my saved trials
Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated:  10/15/2015
Midwest Clinical
mi
from
Moline, IL
Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 10/15/2015
Midwest Clinical
mi
from
Moline, IL
Click here to add this to my saved trials
Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated:  10/15/2015
Research Associates
mi
from
Moline, IL
Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 10/15/2015
Research Associates
mi
from
Moline, IL
Click here to add this to my saved trials
Effect of Antireflux Therapy on the Expression of Genes in Patients With GERD
Effect of Antireflux Therapy on the Expression of Genes Known to be Important in Inflammation, Metaplasia and Neoplasia in Patients With GERD
Status: Enrolling
Updated:  10/23/2015
Strong Memorial Hospital
mi
from
Rochester, NY
Effect of Antireflux Therapy on the Expression of Genes in Patients With GERD
Effect of Antireflux Therapy on the Expression of Genes Known to be Important in Inflammation, Metaplasia and Neoplasia in Patients With GERD
Status: Enrolling
Updated: 10/23/2015
Strong Memorial Hospital
mi
from
Rochester, NY
Click here to add this to my saved trials
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
mi
from
Anaheim, CA
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated:  11/19/2015
mi
from
Isidro Casanova, La Matanza,
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 11/19/2015
mi
from
Isidro Casanova, La Matanza,
Click here to add this to my saved trials
Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
mi
from
Moline, IL
Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
mi
from
Moline, IL
Click here to add this to my saved trials
Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated:  11/19/2015
mi
from
Buenos Aires,
Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 11/19/2015
mi
from
Buenos Aires,
Click here to add this to my saved trials
Intravenous (IV) Pantoprazole for Gastroesophageal Reflux Disease (GERD) in Neonates and Infants
A Multicenter, Open-label, Single and Multiple Dose Pharmacokinetic Study of IV Pantoprazole in Preterm Infants and Infants 0-11 Months With a Clinical Diagnosis of Gastroesophageal Reflux Disease (GERD) or the Need for Acid Suppression
Status: Enrolling
Updated:  12/1/2015
University of Louisville Research Foundation, Inc/KCPCRU
mi
from
Louisville, KY
Intravenous (IV) Pantoprazole for Gastroesophageal Reflux Disease (GERD) in Neonates and Infants
A Multicenter, Open-label, Single and Multiple Dose Pharmacokinetic Study of IV Pantoprazole in Preterm Infants and Infants 0-11 Months With a Clinical Diagnosis of Gastroesophageal Reflux Disease (GERD) or the Need for Acid Suppression
Status: Enrolling
Updated: 12/1/2015
University of Louisville Research Foundation, Inc/KCPCRU
mi
from
Louisville, KY
Click here to add this to my saved trials
Improving Metoclopramide Prescribing Practices at Penn Through a Physician-targeted Intervention
Improving Metoclopramide Prescribing Practices at Penn Through a Physician-targeted Intervention
Status: Enrolling
Updated:  12/3/2015
University of Pennsylvania Center for Clinical Epidemiology and Biostatistics
mi
from
Philadelphia, PA
Improving Metoclopramide Prescribing Practices at Penn Through a Physician-targeted Intervention
Improving Metoclopramide Prescribing Practices at Penn Through a Physician-targeted Intervention
Status: Enrolling
Updated: 12/3/2015
University of Pennsylvania Center for Clinical Epidemiology and Biostatistics
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)
Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)
Status: Enrolling
Updated:  12/7/2015
Ochsner Medical Center
mi
from
Kenner, LA
Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)
Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)
Status: Enrolling
Updated: 12/7/2015
Ochsner Medical Center
mi
from
Kenner, LA
Click here to add this to my saved trials
Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)
Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)
Status: Enrolling
Updated:  12/7/2015
Medical University of South Carolina
mi
from
Charleston, SC
Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)
Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)
Status: Enrolling
Updated: 12/7/2015
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)
Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)
Status: Enrolling
Updated:  12/7/2015
Virginia Commonwealth University
mi
from
Richmond, VA
Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)
Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)
Status: Enrolling
Updated: 12/7/2015
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD
A Multi-Center Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Study of XP19986 in Subjects With Symptomatic Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated:  12/30/2015
MDS Pharma Services
mi
from
Irvine, CA
An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD
A Multi-Center Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Study of XP19986 in Subjects With Symptomatic Gastroesophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 12/30/2015
MDS Pharma Services
mi
from
Irvine, CA
Click here to add this to my saved trials
Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD)
Evaluation of the Medigus SRS Endoscopic Stapling System for the Treatment of Gastro-Esophageal Reflux Disease (GERD)
Status: Enrolling
Updated:  12/30/2015
UC San Diego
mi
from
San Diego, CA
Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD)
Evaluation of the Medigus SRS Endoscopic Stapling System for the Treatment of Gastro-Esophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 12/30/2015
UC San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD)
Evaluation of the Medigus SRS Endoscopic Stapling System for the Treatment of Gastro-Esophageal Reflux Disease (GERD)
Status: Enrolling
Updated:  12/30/2015
Indiana University Hospital
mi
from
Indianapolis, IN
Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD)
Evaluation of the Medigus SRS Endoscopic Stapling System for the Treatment of Gastro-Esophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 12/30/2015
Indiana University Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD)
Evaluation of the Medigus SRS Endoscopic Stapling System for the Treatment of Gastro-Esophageal Reflux Disease (GERD)
Status: Enrolling
Updated:  12/30/2015
Akh Vienna City General Hospital
mi
from
Vienna,
Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD)
Evaluation of the Medigus SRS Endoscopic Stapling System for the Treatment of Gastro-Esophageal Reflux Disease (GERD)
Status: Enrolling
Updated: 12/30/2015
Akh Vienna City General Hospital
mi
from
Vienna,
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Two Period Crossover, Single Dose-Finding Study to Assess the Efficacy and Safety of Controlled Release XP19986 in Patients With Gastroesophageal Reflux Disease
Status: Enrolling
Updated:  12/30/2015
Clinical Research Facility
mi
from
Stanford, CA
A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Two Period Crossover, Single Dose-Finding Study to Assess the Efficacy and Safety of Controlled Release XP19986 in Patients With Gastroesophageal Reflux Disease
Status: Enrolling
Updated: 12/30/2015
Clinical Research Facility
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Two Period Crossover, Single Dose-Finding Study to Assess the Efficacy and Safety of Controlled Release XP19986 in Patients With Gastroesophageal Reflux Disease
Status: Enrolling
Updated:  12/30/2015
Clinical Research Facility
mi
from
Charleston, SC
A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Two Period Crossover, Single Dose-Finding Study to Assess the Efficacy and Safety of Controlled Release XP19986 in Patients With Gastroesophageal Reflux Disease
Status: Enrolling
Updated: 12/30/2015
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Two Period Crossover, Single Dose-Finding Study to Assess the Efficacy and Safety of Controlled Release XP19986 in Patients With Gastroesophageal Reflux Disease
Status: Enrolling
Updated:  12/30/2015
Clinical Research Facility
mi
from
Tacoma, WA
A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Two Period Crossover, Single Dose-Finding Study to Assess the Efficacy and Safety of Controlled Release XP19986 in Patients With Gastroesophageal Reflux Disease
Status: Enrolling
Updated: 12/30/2015
Clinical Research Facility
mi
from
Tacoma, WA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)
Status: Enrolling
Updated:  12/30/2015
Clinical Research Facility
mi
from
Huntsville, AL
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)
Status: Enrolling
Updated: 12/30/2015
Clinical Research Facility
mi
from
Huntsville, AL
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)
Status: Enrolling
Updated:  12/30/2015
Clinical Research Facility
mi
from
Chandler, AZ
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)
Status: Enrolling
Updated: 12/30/2015
Clinical Research Facility
mi
from
Chandler, AZ
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)
Status: Enrolling
Updated:  12/30/2015
Clinical Research Facility
mi
from
Mesa, AZ
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)
Status: Enrolling
Updated: 12/30/2015
Clinical Research Facility
mi
from
Mesa, AZ
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)
Status: Enrolling
Updated:  12/30/2015
Clinical Research Facility
mi
from
Scottsdale, AZ
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)
Status: Enrolling
Updated: 12/30/2015
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)
Status: Enrolling
Updated:  12/30/2015
Clinical Research Facility
mi
from
Tucson, AZ
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)
Status: Enrolling
Updated: 12/30/2015
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)
Status: Enrolling
Updated:  12/30/2015
Clinical Research Facility
mi
from
Sherwood, AR
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)
Status: Enrolling
Updated: 12/30/2015
Clinical Research Facility
mi
from
Sherwood, AR
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)
Status: Enrolling
Updated:  12/30/2015
Clinical Research Facility
mi
from
Anaheim, CA
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)
Status: Enrolling
Updated: 12/30/2015
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)
Status: Enrolling
Updated:  12/30/2015
Clinical Research Facility
mi
from
Lancaster, CA
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)
Status: Enrolling
Updated: 12/30/2015
Clinical Research Facility
mi
from
Lancaster, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)
Status: Enrolling
Updated:  12/30/2015
Clinical Research Facility
mi
from
Mission Hills, CA
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)
Status: Enrolling
Updated: 12/30/2015
Clinical Research Facility
mi
from
Mission Hills, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)
Status: Enrolling
Updated:  12/30/2015
Clinical Research Facility
mi
from
Sacramento, CA
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)
Status: Enrolling
Updated: 12/30/2015
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)
Status: Enrolling
Updated:  12/30/2015
Clinical Research Facility
mi
from
San Diego, CA
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)
Status: Enrolling
Updated: 12/30/2015
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials